Duncker Streett & Co. Inc. Boosts Holdings in Merck & Co., Inc. $MRK

Key Points

• Duncker Streett & Co. Inc. boosted its position in Merck by 110.4% in Q4 to 63,287 shares (worth $6.66M), making MRK its 19th-largest holding at about 1.2% of the firm's portfolio.
• Insiders sold 320,176 shares (~$38.28M) over the past three months, including Johannes Jacobus Oosthuizen (15,000 shares, ~$1.83M) and EVP Jennifer Zachary (121,573 shares, ~$14.49M), leaving insiders with just 0.09% ownership.
• Recent positive catalysts — an FDA priority review for KEYTRUDA with Padcev and EU approval for the RSV antibody Enflonsia — plus several analyst price-target upgrades have supported a "Moderate Buy" consensus (avg target $128.47), though valuation concerns remain after a ~58% one-year rally.

Duncker Streett & Co. Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 110.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,287 shares of the company's stock after buying an additional 33,202 shares during the quarter. Merck & Co., Inc. accounts for approximately 1.2% of Duncker Streett & Co. Inc.'s investment portfolio, making the stock its 19th largest position. Duncker Streett & Co. Inc.'s holdings in Merck & Co., Inc. were worth $6,662,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Darwin Wealth Management LLC boosted its stake in Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock worth $26,000 after buying an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC boosted its stake in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock worth $30,000 after buying an additional 266 shares during the period. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the third quarter worth $31,000. Wealth Watch Advisors INC purchased a new position in Merck & Co., Inc. during the third quarter worth $34,000. Finally, Deane Retirement Strategies Inc. purchased a new position in Merck & Co., Inc. during the third quarter worth $35,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the completion of the sale, the insider directly owned 21,197 shares of the company's stock, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the company's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares of the company's stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. Insiders own 0.09% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA granted priority review for two supplemental BLAs to use KEYTRUDA (and KEYTRUDA QLEX) with Padcev for cisplatin‑eligible muscle‑invasive bladder cancer — a meaningful potential label expansion for a high‑value oncology franchise that can drive upside if approved. FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX with Padcev
• Positive Sentiment: European approval for Enflonsia (RSV antibody) for infants broadens Merck’s pediatric preventive portfolio and creates a new revenue stream in a large seasonal market. Merck Secures EU Nod for RSV Antibody Enflonsia in Infants
• Positive Sentiment: Market reaction earlier reflected the regulatory news — shares climbed intraday after the priority review announcement, showing investor appetite for the clinical/label expansion story. Merck Shares Climb After KEYTRUDA Priority Review
• Neutral Sentiment: Market commentary highlights Merck’s strong recent performance (outpacing the S&P) and lists reasons to like the stock, but also frames a valuation debate after the rally — useful context but not an immediate catalyst. 3 Reasons We Love Merck (MRK)
• Neutral Sentiment: Industry/market reports (e.g., filtration/biologics manufacturing trends) note secular tailwinds for biologics makers, which supports long‑term demand for Merck’s biologics‑related services and supplies. Healthcare Filtration Markets 2025-2035
• Negative Sentiment: Analysts and headlines are asking whether the ~58% one‑year surge has priced in most upside; combined with profit‑taking after the rally, this creates downward pressure and helps explain today’s pullback. Has The 58% One Year Surge In Merck (MRK) Gone Too Far On Valuation?
• Negative Sentiment: Note: Zacks flagged that Merck’s decline today exceeded the broader market’s, indicating intraday selling pressure that may reflect short‑term traders trimming positions. Merck Sees a More Significant Dip Than Broader Market

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price objective for the company in a research note on Friday, February 13th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. Cantor Fitzgerald lifted their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. Wolfe Research raised shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 target price for the company in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $128.47.

Merck & Co., Inc. Stock Down 1.6%

Shares of MRK opened at $117.15 on Tuesday. The firm has a market capitalization of $289.34 billion, a P/E ratio of 16.09, a P/E/G ratio of 2.39 and a beta of 0.26. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average price of $119.11 and a 200-day moving average price of $106.32.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business's revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts expect that Merck & Co., Inc. will post 4.93 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.'s payout ratio is currently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.